2016
The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models
Khlestova E, Johnson JW, Krystal JH, Lisman J. The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models. Journal Of Neuroscience 2016, 36: 11151-11157. PMID: 27807157, PMCID: PMC5148234, DOI: 10.1523/jneurosci.1203-16.2016.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrainEvidence-Based MedicineHallucinogensHumansKetaminePsychoses, Substance-InducedReceptors, N-Methyl-D-AspartateSchizophreniaConceptsNMDAR antagonistsNMDA receptor hypofunction hypothesisDifferent NMDAR subtypesHealthy human subjectsSymptoms of schizophreniaPsychotogenic effectsNMDA receptorsNMDAR subtypesSchizophrenia modelKetamine's abilityNegative symptomsKetamineMultiple subtypesPsychotic statesPreferential involvementSchizophreniaAntagonistGluN2CSubtypesReceptorsEEG powerHuman subjectsNMDARSymptomsΔ oscillations
2011
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence
Soyka M, Kranzler HR, van den Brink W, Krystal J, Möller HJ, Kasper S, Treatment G. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. The World Journal Of Biological Psychiatry 2011, 12: 160-187. PMID: 21486104, DOI: 10.3109/15622975.2011.561872.Peer-Reviewed Original ResearchMeSH KeywordsAdultAryl Hydrocarbon HydroxylasesBuprenorphineCytochrome P-450 CYP2B6Cytochrome P-450 CYP2D6Drug Therapy, CombinationEvidence-Based MedicineGenetic VariationHumansMethadoneNarcotic AntagonistsNarcoticsOpiate Substitution TreatmentOpioid-Related DisordersOxidoreductases, N-DemethylatingPsychotherapyReceptors, OpioidSocial SupportStandard of CareSubstance Withdrawal SyndromeConceptsOpioid dependenceOpioid abusePractice guidelinesEvidence-based practice guidelinesBiological Psychiatry (WFSBP) GuidelinesOpioid agonist methadoneSecond-line medicationsNational treatment guidelinesNumber of medicationsEfficacy of methadoneOpioid use disorderEvidence-based guidelinesRandomized clinical trialsCombination of buprenorphineWorld FederationInternational task forceStrength of evidenceOpioid withdrawalAdjunctive medicationsOpioid maintenanceTreatment guidelinesTask ForceCochrane LibraryPharmacological treatmentClinical trials